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ABSTRACT
Prostaglandin E2 (PGE2) is produced by resident cells
in the airway, such as airway epithelial cells, airway
smooth muscle cells and alveolar macrophages, and
is always present in the airway. Various exogenous and
endogenous stimuli cause immediate increases in
PGE2 from several-fold to multiples of 10-fold. Prosta-
glandin E2 controls the function of cells that contribute
to immune and inflammatory responses, such as
lymphocytes, eosinophils, mast cells, macrophages
and polymorphonuclear cells, and exhibits suppressor
activity in the initial and advanced stages of allergic
airway inflammation (establishment of sensitization,
induction of early asthmatic response, chemotaxis
of inflammatory cells and continuation of the late
asthmatic response). Therefore, if the endogenous
protective effects of PGE2 are weakened or absent,
inflammation and hypersensitive responses readily
occur in the airway. Although the effects of PGE2
remain to be clarified, the possibility of the involve-
ment of decreased PGE2 activity in the pathogenesis of
asthma exists. However, in aspirin-induced asthma the
role of PGE2 as a protective factor, through an as yet
undetermined mechanism, is marked. It is thought
that, in this type of asthma, symptoms may be induced
by the elimination of the protective action of PGE2 by
non-steroidal anti-inflammatory drugs (NSAID). It is
possible that PGE2 agonists that produce little airway
irritation and drugs that raise the endogenous PGE2
level have potential as new types of anti-inflammatory
or anti-asthma drugs.
Key words: airway inflammation, arachidonic acid,
aspirin-induced asthma, asthma, cyclo-oxygenase,
prostaglandin E2.
INTRODUCTION
In the present review article, the role of prostaglandin
(PG)E2 as an endogenous protective factor in the patho-
physiology of allergic pulmonary diseases, especially
bronchial asthma, will be discussed. The pathophysiology
of bronchial asthma is complex and multifaceted and has
been studied from many points of view. As to the mech-
anism of the development of allergic asthma, it has
recently been hypothesized that eosinophils and mast
cells interact with a cytokine network, with the lymphocyte
at its center, and that the production of IgE antibodies,
production and release of inflammatory mediators and
impairment of airway epithelial cells result, causing the
so-called ‘eosinophilic inflammation’ of the airway.1 In
this process, various arachidonic acid metabolites con-
tribute to the pathophysiology of asthma.2 Almost all
arachidonic acid metabolites, such as leukotriene (LT)C4,
thromboxane (TX)A2 and PGD2, cause airway inflam-
mation and constriction and, thus, act to initiate or
aggravate asthma, but there is evidence that PGE2 acts as
a mediator that possesses endogenous anti-inflammatory
and bronchoprotective effects.2
ARACHIDONIC ACID METABOLITES AND THE
PATHOPHYSIOLOGY OF BRONCHIAL ASTHMA
Figure 1 shows the principal metabolic pathways of
arachidonic acid. Arachidonic acid is bound to the
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C2 position of the glycerol of phospholipids that form cell
walls and is released by the enzyme action of phospho-
lipase A2, whereupon it immediately acts as a substrate
for cyclo-oxygenase (COX) and 5-lipoxygenase (5-LO).
In this metabolic pathway, there are many mediators that
can contribute to the pathophysiology of asthma.2 For
example, peptide LT and platelet-activating factor (PAF),
TXA2, PGF2a and PGD2 contribute to the contraction of
bronchial smooth muscles and the peptide LT PGE2,
PGD2 and PAF contribute to increased vascular perme-
ability. Peptide LT and 5-hydroxyeicosatetraenoic acid
(5-HETE) contribute to the secretion of mucus in the
airway and LTB4, 5-HETE and PAF promote the chemo-
taxis of inflammatory cells into the airway. Furthermore,
the peptide LT TXA2 and PAF are said to promote bron-
chial hyperresponsiveness.2,3 In addition, active oxygen
radicals are produced in these metabolic processes,
which may also contribute to injury of the airway epithe-
lium. However, PGE2 has been found to have a number
of protective actions: it dilates the human bronchi,4,5
inhibits early and late airway responses to antigen inha-
lation6 etc. Furthermore, these metabolites not only act
directly on target cells as effectors but, as modulators,
they also affect the production of cytokines,7 the activity
of the autonomic nervous system (ANS)8 and the acti-
vation of mast cells.9 Conversely, the metabolic pathways
of arachidonic acid are modulated at various stages by
mediators of the ANS, glucocorticoids,10 cytokines11,12
and nitric oxide (NO).13
The principal metabolic pathways are the COX and 5-LO
pathways, but there are also pathways through 12-LO,
15-LO and cytochrome P450.14 Although not shown in
Fig. 1, some non-enzymatic metabolites also have physio-
logical activity. Furthermore, COX has two isozymes,
COX1 and COX2, and conventional NSAID have almost
no inhibitory activity on COX2.15 Among these meta-
bolites, the peptide LT and TXA2 are especially important as
mediators that contribute directly to the genesis of asthma
symptoms and it is well known that drugs that act as antag-
onists to them and those that inhibit their synthesis are now
available as a new class of asthma drugs. Although all cells
contain arachidonic acid (the substrate for COX and 5-LO)
in their cell walls, not all the metabolic pathways described
here are present in all cells.
Table 1 summarizes the production of prostanoids by
resident cells in the lung and inflammatory cells. Alveolar
macrophages produce almost all the prostanoids LTC4,
LTB4 and PAF. Mast cells produce PGD2, PGF2a and TXA2,
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Fig. 1 Metabolic pathways of arachidonic acid. 5-LO, 5-lipoxygenase; COX, cyclo-oxygenase; EET, epoxyeicosatrienoic acid; FLAP,
5-lipoxygenase-activating protein; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; LT, leukotriene;
PAF, platelet-activating factor; PG, prostaglandin; TX, thromboxane; PLA2, phospholipase A2.
as well as LTC4 and PAF, and airway epithelial cells
produce all the prostanoids mentioned here. The impor-
tance of airway epithelial cells as effector cells has been
suggested and there are reports that PGE2 and PGI2 are
even produced in airway smooth muscle cells.16,17 Further-
more, the prostanoids present in lung tissue and airways
are derived from many cells. It has been shown that PGE2
is produced by resident cells in the lung, such as alveolar
macrophages, airway epithelial cells and airway smooth
muscle cells, as well as by neutrophils and eosinophils.
PROSTAGLANDIN E RECEPTORS
The activity of PGE2 is expressed through specific recep-
tors (EP receptors), four subtypes, EP1, EP2, EP3 and EP4,
which have been cloned and are closely related to the
older pharmacological classification.18 Table 2 shows the
order of affinities of the PGE2 agonists to the various
receptors.18 Table 3 shows the intracellular signal trans-
duction systems that are related to the various EP
receptors.18 The EP2 and EP4 receptors are related to the
Gs-protein, cause elevations in intracellular cyclic AMP
(cAMP) concentrations and are thought to mediate the
activity of PGE2 as a protective factor. The principal signal
transduction pathway of the EP3 receptor is the inhibition
of adenylate cyclase by way of the Gi-protein; this recep-
tor has four isoforms, A, B, C and D, and is thought to be
linked with various different signal transduction systems.18
The multiplicity of EP receptors leads to the multiplicity
and complexity of PGE2 activity and, indeed, different
concentrations of PGE2 can cause completely opposite
reactions in the same tissues and different reactions in
different species.18
ENDOGENOUS PROTECTIVE FACTORS RELATED
TO THE PATHOGENESIS OF ASTHMA
Among the endogenous protective factors against asthma
symptoms, of primary consideration is the adreno-
medullary sympathetic nervous system and epinephrine
and norepinephrine, which act as mediators in this
system. Additionally, the non-adrenergic, non-cholinergic
inhibitory nervous system is protective and vasoactive
intestinal peptide (VIP) and NO are considered to be the
mediators of this system in humans. The glucocorticoids
are also important protective factors. Among the eicosan-
oids, PGE2 seems to be the only certain protective factor.
When these protective factors fail to act normally, asthma
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Table 1 Resident and inflammatory cell sources of
prostanoids in the lung2
PG, prostaglandin; TX, thromboxane.
Table 2 Binding characteristics of prostaglandin E (EP)
receptor subtypes18
*Ligand: [3H]-prostaglandin (PG)E2.
Table 3 Second messengers associated with EP receptor
subtypes18
cAMP, cyclic AMP; EP, prostaglandin E receptor subtypes.
Cell type Prostanoid mediator
PGD2 PGF2a TXA2 PGE2 PGI2
Resident cells
Alveolar macrophage s s s s
Mast cell s s s
Airway epithelium s s s s s
Airway smooth muscle s s
Vascular smooth muscle s
Vascular endothelium s s
Inflammatory cells
Neutrophil s s
Eosinophil s s s
Mononuclear s
Subtype Kd Rank order of binding affinity
(nmol/L)*
EP1 21 PGE2 ‡ iloprost > PGE1 > PGF2a
> PGD2
17-phenyl-PGE2 > sulprostone
>> AH6809, butaprost
EP2 40 (?) PGE2 = PGE1 >> PGD2, PGF2a
11-deoxy-PGE1 = 16, 16-dimethyl-
PGE2 > butaprost > AH13205,
19(R)-OH-PGE2 > 1-OH-PGE1,
M&B-28767 >> sulprostone = 0
EP3 3 PGE2 = PGE1 >> iloprost > PGD2
> PGF2a
M&B-28767 >>> butaprost,
SC19220 = 0
EP4 11 PGE2 = PGE1 >> PGD2, PGF2a , iloprost
11-deoxy-PGE1 > misoprostol,
M&B-28767 > AH23848 >>
sulprostone, butaprost = 0
Subtype Isoform G-protein Second messenger
EP1 G (?) Ca2+ ›
EP2 Gs (?) cAMP ›
EP4 Gs cAMP ›
EP3 EP3A Gi cAMP fl
EP3B Gs cAMP ›
EP3C Gs cAMP ›
EP3D Gi, Gs, Gq cAMP fl , cAMP › ,
Phosphatidylinositol
response
attacks may be induced. A classic example is the induc-
tion of asthma by b -adrenergic antagonists. Furthermore,
as will be discussed later, findings indicate that the induc-
tion of asthma by NSAID in patients with aspirin-induced
asthma is due to the abolition of the activity of PGE2 as a
protective factor.19 Asthma attacks induced by the failure
of protective factors, such as those due to b -adrenergic
antagonists and NSAID, are so violent that they may
be fatal.
Prostaglandin E2 has been widely recognized as a
cytoprotective PG in the stomach mucosa20 and PGE
derivatives are used as therapy for stomach ulcers. A
large quantity of PGE2 is also produced from the airway
epithelium, as with the stomach mucosa,21,22 but there
have been few studies of the role that it may play.
PROSTAGLANDIN E2-PRODUCING CELLS IN
THE AIRWAY
Prostaglandin E2 is present in human bronchoalveolar
lavage fluid (BALF),23 sputum24 and airway secretions.25
Large quantities of PGE2, as well as PGF2a and TXB2, are
present in the sputum of subjects with chronic inflam-
matory airway diseases, such as chronic bronchitis and
chronic bronchiolitis; quantities of these prostanoids can
be decreased by the inhalation of indomethacin.24
Concentrations of PGE2, PGF2a , 6-keto-PGF1a and TXB2
in the epithelial lining fluid in the lower respiratory tract
are more than 10-fold higher than in plasma and it has
been reported that such concentrations of PGE2 are as
high as 100-fold the plasma concentration.25 A basal
level of release of the peptide LT, TXB2 and PGE2 from
human bronchial biopsy specimens has been observed
and, with the addition of arachidonic acid, such quanti-
ties increase several fold.26 In particular, large quantities
of PGE2 and TXB2 are produced from inflamed bronchial
epithelium.26 Cultured epithelial cells from the bovine
trachea produce large amounts of PGE2 in a dose-
dependent manner when exposed to ozone.22 However,
PGF2a and inflammatory and broncospastic eicosanoids,
such as TXB2 and LTB4, are also produced at the same
time.22 Cultured human tracheal epithelial cells produce
large quantities of PGE2 when stimulated with endoge-
nous stimulants, such as bradykinin and calcium
ionophore A23187, if serum is present.21 Furthermore,
cultured human tracheal smooth muscle cells produce
PGE in a dose-dependent manner when stimulated with
bradykinin.16 Prostaglandin E2 is constantly present in
the airway, as mentioned earlier, and is mainly produced
by resident cells, such as airway epithelial and smooth
muscle cells. Moreover, the quantity of PGE2 produced is
immediately increased several fold, or even by multiples
of 10-fold, by endogenous or exogenous stimuli to reach
levels at which it exhibits physiological activity.27
INHIBITORY EFFECTS OF PGE2 ON VARIOUS
INFLAMMATORY CELL FUNCTIONS
Prostaglandin E2 inhibits the production and release of
mediators from various kinds of inflammatory cells. For
example, PGE2 or the PGE analog misoprostol inhibit the
generation of superoxide anions from inflammatory cells,
including alveolar macrophages and eosinophils,28 and
they inhibit eosinophil chemotaxis induced by C5a and
PAF,7 IL-5- and IL-3-induced prolongation of eosinophil
survival7 and the production of LTB4 and 5-HETE from
human polymorphonuclear leukocytes.29 In addition, PGE2
and misoprostol inhibit granulocyte–macrophage colony
stimulating factor (GM-CSF)7 and IL-4-induced IgE pro-
duction by peripheral blood lymphocytes,30 as well as
anti-IgE-induced histamine release from chopped human
lung and dispersed human lung mast cells.9 Prostaglandin
E has a strong inhibitory effect on the function of T cells
and it inhibits proliferation responses induced by mitogen
stimulants, such as concanavalin A and phytohemag-
glutinin, as well as the production of lymphokines, such
as macrophage-stimulating factor and IL-2, and the
induction of cytotoxic T cells.31,32 These inhibitory effects
are accompanied by increased cAMP in the cells33 and
are thought to be mediated by EP2 and EP4 receptors.
Thus, PGE2 exhibits various inhibitory activities at various
stages (establishment of sensitization, induction of imme-
diate responses, chemotaxis of inflammatory cells and
continuation of delayed responses) in the establishment
and progression of allergic airway inflammation. There
are a large variety of target cells, including lymphocytes,
mast cells, eosinophils, alveolar macrophages and poly-
morphonuclear leukocytes.
EFFECTS OF PGE2 ON AIRWAY SMOOTH
MUSCLES AND THE CHOLINERGIC NERVOUS
SYSTEM IN THE AIRWAY
That inhaled PGE2 dilates the human airway has been
known for more than 20 years.4,5 However, because
PGE2 stimulates afferent C fibers of the airway, it induces
coughing34 and, therefore, its clinical use as a broncho-
dilator has been restricted. Experiments using canine
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and human airways have shown that endogenous PGE2,
at low concentrations, inhibits the release of acetyl-
choline from the nerve ends of the cholinergic nervous
system and inhibits neurotransmission through the
vagus.35
ACTIVITY OF VASODILATION AND INCREASING
BLOOD FLOW: ADVANTAGEOUS OR NOT?
Prostaglandin E2 promotes vasodilation of the small
arteries and increases in local blood flow.36,37 This activity,
in the case of hypersensitivity responses, may promote
local blood vessel permeability, with the unfavorable
consequence of edema. Prostaglandin E2 markedly
increases plasma extravasation due to histamines, LTC4
and LTB4,36,37 but does not cause plasma leakage by
itself.37 Indomethacin increases local plasma extravasa-
tion due to an immediate allergic response and this
activity is nullified by the pre-administration of PGE2.37
Thus, PGE2 increases the activity of the released media-
tors of plasma extravasation by vasodilation and increased
blood flow, but its net effect during the hypersensitivity
response is probably to inhibit plasma leakage by inhibit-
ing the endogenous production and release of vasoactive
mediators. Increases in local blood flow promote local
clearance of harmful substances and could, conceivably,
be one of the protective activities of PGE2.
INHIBITORY EFFECTS OF EXOGENOUS PGE2 IN
HYPERSENSITIVITY RESPONSES
Exogenous PGE2 inhibits various hypersensitivity re-
sponses. The inhalation of PGE1 or PGE2 inhibits
histamine-induced anaphylaxis in guinea-pigs, with an
effect greater than that of isoproterenol.38 The PGE1
analog misoprostol inhibits human Arthus-type skin
reactions induced by mite antigens.7 This effect is due
to inhibition of the infiltration of inflammatory cells into
the locality.7 The inhalation of PGE2 not only inhibits
human immediate and late asthma responses induced by
the inhalation of allergens, but also suppresses the
accompanying phenomenon of the promotion of airway
hypersensitivity.6 The inhalation of PGE2 suppresses
exercise-induced asthma in humans, but does not affect
the methacholine inhalation threshold value.39 Thus, the
activity of PGE2 is not due to direct action on the smooth
muscles, such as bronchodilator activity in the airway, but
probably due to an inhibition of the release of inflam-
matory and bronchoconstrictor mediators.
INHIBITION OF AIRWAY RESPONSES DUE TO
INDUCTION OF ENDOGENOUS PGE: INDUCTION
OF REFRACTORINESS AND EFFECTS OF
FUROSEMIDE INHALATION
The results discussed so far concern investigations of the
effects of exogenous PGE2, but there are also several
reports suggesting the possibility that endogenous PGE
suppresses airway responses. The weakening or disap-
pearance of airway responses is seen after the inhalation
of distilled water,40 after exercise-induced asthma
attacks41,42 and after the inhalation of sodium metabi-
sulfite.41,43 However, this phenomenon of ‘refractoriness’
disappears when NSAID, such as indomethacin, are
administered before an event that may produce an
airway response and it is said that the production of PG,
including PGE2, also contributes to this effect.40,42,43
Furthermore, the inhalation of furosemide suppresses
antigen-induced airway responses,44 exercise-induced
asthma45 and aspirin-induced asthma.46 The inhalation
of furosemide is also sometimes effective against natural
asthma symptoms.47 It has been shown that furosemide
increases PGE production in a dose-dependent manner
in the renal medulla of rats48 and it is possible that the
inhibitory activity of furosemide in the airway is also
mediated by the production of endogenous PGE2.
THE IMPORTANCE OF PGE2 AS AN
ENDOGENOUS PROTECTIVE FACTOR IN
ASPIRIN-INDUCED ASTHMA
As mentioned previously, there is a strong possibility that
PGE may act as an endogenous protective factor in
hypersensitivity responses of various types in the airway.
However, because the administration of NSAID does not
worsen asthma, except in those patients with aspirin-
induced asthma, it appears that the bronchoprotective
role of basal PGE2 production is not very important in
most patients with asthma. However, PGE play an impor-
tant role as endogenous protective factors against
aspirin-induced asthma, and several studies have shown
that aspirin-induced asthma can lead to PGE-addicted or
-dependent states.19,23,49 In aspirin-induced asthma, the
PGE2 level in BALF is high and PGE2 levels are reduced,
together with levels of other PG, by the inhalation of
lysine–aspirin, thereby inducing asthma attacks in
patients.23 However, if such patients are pretreated with
inhaled PGE2, the airway response to the inhalation of
lysine–aspirin is inhibited, as is the elevation of urinary
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LTE4.19 Also, if a minute quantity of PGE1 sufficient for the
maintenance of physiological concentrations is continu-
ously drip infused into subjects with aspirin-induced
asthma who also have mite hypersensitivity, airway
responses to the inhalation of mite antigens is not inhib-
ited, but the hypersensitive response to intravenous
injections of lysine–aspirin is completely inhibited.49
Furthermore, airway dilation in response to inhaled PGE1
is reduced in cases of aspirin-induced asthma50 and tachy-
phylaxis due to increased endogenous PGE is possible.
CONCLUDING REMARKS
Prostaglandin E2 is produced by airway resident cells,
such as airway epithelial cells and smooth muscle
cells, and alveolar macrophages and is always present in
the airway. It is increased immediately after exogenous
or endogenous stimuli from several-fold to multiples of
10-fold. Furthermore, it controls the function of lympho-
cytes, eosinophils, mast cells, macrophages and neutro-
phils, which contribute to the formation of immune and
inflammatory responses.
Prostaglandin E2 is produced locally due to various
stimuli, but PGF2a , TXA2 and peptide LT are also pro-
duced at the same time and we can only observe the net
effects of the interactions of these eicosanoids and other 
mediators. Therefore, unless the effects of PGE2 as an
endogenous protective factor are carefully observed, we
are not aware of its presence. However, PGE2 has strong
inhibitory activity, especially against T lymphocytes, and it
is also possible that it strongly inhibits the formation and
progression of allergic inflammation over the long term.
If the endogenous protective activity of PGE2 is weakened
or lacking, inflammatory and hypersensitive responses in
the airway occur more readily. One cannot deny the
possibility that an insufficiency of this kind of PGE2 bron-
choprotective activity may contribute to the pathogenesis
of asthma. In contrast, in aspirin-induced asthma, the
role of PGE2 as a protective factor seems to be important
and it is thought that asthma symptoms may be induced
by the cancellation of the protective activity of PGE2 by
NSAID. Agonists of PGE2, which produce little airway
irritation, and drugs that raise the endogenous PGE2 level
may become new types of anti-inflammatory or anti-
asthma drugs.
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